Immedica publishes Business Review and Annual & Sustainability report 2022

Stockholm, April 26 , 2023 - Immedica has today published its Business review and Annual & Sustainability report 2022.

This is the first report for Immedica in this format. Immedica is a young  and still relatively small company, but our ambitions are nothing but high.

“At Immedica, we believe we have an important role to fill in society in bringing new innovative treatments to patients with rare diseases for whom there are currently no viable treatment options.”
comments Anders Edvell CEO.

The integrated report is attached to his announcement.

About Immedica Pharma
Immedica is pharmaceutical company, headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Immedica’s capabilities cover marketing and sales, compliance, pharmacovigilance, quality assurance, regulatory and medical affairs as well as market access. Serving patients in more than 50 countries, Immedica is fully dedicated to helping those living with diseases which have a large unmet medical need.

Immedica’s therapeutic areas are within genetic & metabolic diseases, hematology & oncology and specialty care.

Immedica was founded in 2018 by the investment company Impilo and Buy-in-Management. Today Immedica employs more than 90 people across Europe and the Middle East.

For more information visit www.immedica.com

Immedica contact:
Linda Holmström
Head of Communication
linda.holmstrom@immedica.com
+ 46 708 73 40 95

Immedica Pharma AB
Solnavägen 3H
SE-113 63 Stockholm